Neuren: In trading halt pending clinical trial announcement

Company News

by Jessica Amir

Neuren Pharmaceuticals Limited (ASX:NEU) has entered into a trading halt pending an announcement about its lead product’s clinical trial.

The company which develops brain injury and disorder treatment requested the halt after the market closed on Friday.

The halt is expected to remain until Wednesday 22 March or until Neuren announces a statement about Phase 2 of its clinical trial in Rett syndrome, and how its lead product trofinetide is used.

The company says its already conducted double-blind placebo-controlled Phase 2 trials in both Rett syndrome and Fragile X syndrome and found benefit from their product, trofinetide.

Shares in Neuren Pharmaceuticals Limited (ASX:NEU) last traded flat on Friday at 8 cents.

Jessica Amir

Finance News Network
Jessica presents the Market Outlook and company news. She joined FNN in January 2017. She has been in broadcast journalism for over five years. She has worked as a journalist with Sky News Business, ABC 1 and ABC24. She has also worked in regional Australia for Prime 7 and WIN News. She is also a qualified financial planner and a Masters of Applied Finance student.